Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.29 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 2:08 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Open
€0.29
Previous Close
€0.29
Day High
€0.29
Day Low
€0.29
52 Week High
11/21/14 - €0.36
52 Week Low
01/20/15 - €0.24
Market Cap
122.4M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
422.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EKF DIAGNOSTICS HOLDINGS PLC (LYF)

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East and Africa, and internationally. It offers glycated hemoglobin (HbA1c) analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes. The company also provides hemoglobin analyzers, including Hemo Control, a hemoglobin analyzer that provides quantitative lab quality results within 25 seconds for blood banks, hospitals, and clinics; Hemo Vet for veterinary use; STAT-Site, a hand-held hemoglobin analyzer; UltraCrit, a hematocrit measurement device for blood donor screening; HemataSTAT, a microhematocrit system, which offers quantitative hematocrit; and DiaSpect Hemoglobin T and DiaSpect Tm, the hemoglobin measurement systems. In addition, it offers glucose analyzers, such as C-Line GP+, C-Line Clinic, and S-Line Lab+ used in laboratories and sports institutions; and lactate analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, as well as Lactate Scout+, a blood lactate analyzer for athletes, coaches, amateurs, and sport scientists. Further, the company provides rapid testing services, including pregnancy tests, such as True20 and QuPID for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY, and Strep A for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. Additionally, it offers Sepsis testing services; clinical chemistry reagents; and diagnostic biomarker-based enzyme-linked immunosorbent assay kits and rapid tests, as well as maternal and women health diagnostic solutions. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

395 Employees
Last Reported Date: 03/16/15
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 238.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Financial Officer, Finance Director, Se...
Total Annual Compensation: 167.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 184.0K GBP
Chief Technology Officer and Executive Direct...
Total Annual Compensation: 182.0K GBP
Compensation as of Fiscal Year 2014.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Announces the Launch of Next Generation Sequencing Technology Precisionpath in Partnership with Greenville Health Systems

EKF Diagnostics Holdings plc announced the launch of its next generation sequencing technology PrecisionPath in partnership with Greenville Health Systems. For the first time patients will have wider access to affordable advanced NGS testing that can help doctors determine the most effective cancer treatments based on an individual's genetic profile. The launch of the PrecisionPath Colon by EKF's subsidiary Selah Genomics, follows a successful one year trial with GHS, one of cancer institutes in the US, and will be the first commercial NGS panel molecular test for invasive colon cancer priced under $1,000 with a target turnaround time of less than 7 days per reportable result. PrecisionPath can be used by oncologists nationally to identify the specific growth drivers for colon cancer in an individual based on their genetic make-up and to, ultimately, ensure the most effective therapy is used at all times during treatment. By identifying the cancer's specific susceptibility to available treatments, PrecisionPath will help oncologists select the most effective options for a patient based on the patient's tumor type. The advantage of the PrecisionPath Colon test panel is that it focusses on a key number of actionable biomarkers which provide maximum clinical utility at a more affordable cost. The panel provides a clear and concise report that differentiates between those genes with proven clinical utility and others under clinical trial investigation. As the body of evidence for clinical utility grows, reports will be updated accordingly, providing doctors with a means to routinely integrate genomic analysis into the everyday care of cancer patients. Initially PrecisionPath Colon will be available across GHS's oncology treatment centres. In Europe, it is predicted that there will be close to 450,000 new cases of colorectal cancer diagnosed in 2015. EKF will then expand the service throughout the US targeting oncologists and pathologists treating patients with invasive CRC. EKF intends to offer PrecisionPath™ in additional indications, including lung cancer, breast cancer and melanoma beginning in late 2015.

EKF Diagnostics Holdings plc Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014

EKF Diagnostics Holdings plc reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company’s revenues were up 26% to £40.1 million against £31.8 million a year ago. Adjusted EBITDA was up 31% to £6.3 million against £4.8 million a year ago. Operating loss was £2.5 million against operating profit of £2.4 million a year ago. EBITDA before exceptional items and share-based payments was £6.257 million against £4.824 million a year ago. Loss before income tax was £4.028 million against profit before income tax of £0.607 million a year ago. Loss attributable to owners of the parent was £5.689 million or £1.50 per diluted share against £1.126 million or £0.41 per diluted share a year ago. Net cash used in operating activities was £4.744 million against net cash generated by operating £2.007 million a year ago. Purchase of property, plant and equipment was £1.038 million against £1.185 million a year ago. Purchase of intangibles was £1.595 million against £1.097 million a year ago.

EKF Diagnostics Holdings plc, Annual General Meeting, May 19, 2015

EKF Diagnostics Holdings plc, Annual General Meeting, May 19, 2015., at 14:00 GMT Standard Time. Location: offices of Panmure Gordon.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.29 EUR 0.00

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies
 

Industry Analysis

LYF

Industry Average

Valuation LYF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit www.ekfdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.